Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)

Main inclusion criteria: * Patients diagnosed as definite, probable or probable-laboratory-supported ALS according to El Escorial Criteria. * Patients of less than 2 years after the onset of ALS. * Patients who meet the criteria of K-ALSFRS-R score and forced vital capacity. Main exclusion criteria: * Patients with primary lateral sclerosis, progressive muscular atrophy or lower motor neuron disease. * Patients who have history of ALS treatment of edaravone or stem cell therapy within 16 weeks before screening. * Patients who have permanently ceased the administration of riluzole due to lack of tolerability and/or efficacy. * Patients in Class II to IV according to the New York Heart Association functional classification. Patients with myocardial infarction, unstable arrhythmia, and/or significant cardiovascular disease such as unstable angina within 12 weeks before screening. * Patients who do not meet the criteria of laboratory tests and medical/operation history.